- Home
- HRMY vs IMCR Comparison
HRMY vs IMCR Comparison
Compare HRMY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- IMCR
- Stock Information
- Founded
- HRMY 2017
- IMCR 2008
- Country
- HRMY United States
- IMCR United Kingdom
- Employees
- HRMY N/A
- IMCR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRMY Health Care
- IMCR Health Care
- Exchange
- HRMY Nasdaq
- IMCR Nasdaq
- Market Cap
- HRMY 2.1B
- IMCR 1.7B
- IPO Year
- HRMY 2020
- IMCR 2021
- Fundamental
- Price
- HRMY $33.22
- IMCR $32.03
- Analyst Decision
- HRMY Buy
- IMCR Buy
- Analyst Count
- HRMY 9
- IMCR 13
- Target Price
- HRMY $47.00
- IMCR $68.73
- AVG Volume (30 Days)
- HRMY 1.3M
- IMCR 238.6K
- Earning Date
- HRMY 10-29-2024
- IMCR 11-06-2024
- Dividend Yield
- HRMY N/A
- IMCR N/A
- EPS Growth
- HRMY N/A
- IMCR N/A
- EPS
- HRMY 2.11
- IMCR N/A
- Revenue
- HRMY $681,879,000.00
- IMCR $296,312,000.00
- Revenue This Year
- HRMY $24.63
- IMCR $28.88
- Revenue Next Year
- HRMY $18.04
- IMCR $12.61
- P/E Ratio
- HRMY $15.77
- IMCR N/A
- Revenue Growth
- HRMY 25.83
- IMCR 25.09
- 52 Week Low
- HRMY $26.03
- IMCR $29.72
- 52 Week High
- HRMY $41.61
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- HRMY 44.15
- IMCR 56.41
- Support Level
- HRMY $32.37
- IMCR $32.65
- Resistance Level
- HRMY $36.68
- IMCR $34.78
- Average True Range (ATR)
- HRMY 2.02
- IMCR 1.54
- MACD
- HRMY -0.07
- IMCR 0.21
- Stochastic Oscillator
- HRMY 20.73
- IMCR 74.74
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.